Prediction Value of Ecg on Coronary Slow-flow

NCT ID: NCT02650557

Last Updated: 2016-01-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 998 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2015-10-31

Brief Summary

The investigators aimed to investigate the vessel heterogeneity of Thrombolysis in Myocardial Infarction frame count (TFC) in the three coronary arteries, and its relation to P-wave dispersion, in patients with coronary slow flow and otherwise normal coronary arteries.

Detailed Description

Coronary slow flow (CSF) phenomenon, which is characterized by delayed coronary opacification in the absence of obstructive epicardial coronary artery disease, is a relatively common finding in patients undergoing routine coronary angiography and is often associated with chest pain. In some patients with CSF, blood flow may be heterogeneously distributed in the three coronary arteries, suggesting the heterogeneously distributed microvascular dysfunction in the myocardium. However, the vessel heterogeneity of Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) has not been fully elucidated.

P-wave dispersion (PWD) is defined as the difference between the longest and the shortest P-wave duration recorded from multiple different surface electrocardiogram (ECG) leads, and it has been reported to be associated with inhomogeneous and discontinuous propagation of sinus impulses5, which are well known electrophysiologic characteristics of the atrium prone to fibrillation. Although it is plausible to hypothesize that PWD might be associated with the heterogeneously distributed microvascular dysfunction, and previous studies have demonstrated the abnormal PWD in patients with CSF, the correlation between TFC heterogeneity and PWD has never been evaluated.

In this study, the investigators aimed to investigate the vessel heterogeneity of TFC in the three coronary arteries, and its relation to PWD, in patients with CSF and otherwise normal coronary arteries.

Conditions

Coronary Slow Flow

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

CSF group

consecutive patients with angiographically documented CSF

angiography

Intervention Type: PROCEDURE

angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.

control group

age- and gender-matched control subjects

angiography

Intervention Type: PROCEDURE

angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.

Interventions

angiography

angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• All of the subjects had chest pain and were referred to our catheterization laboratory for coronary angiography

Exclusion Criteria

• Valvular or congenital heart disease
• Atrial fibrillation or other arrhythmia that would interfere with ECG analysis
• Left ventricular hypertrophy
• Myocardial or pericardial disease
• Chronic obstructive pulmonary disease, or electrolyte abnormalities.
• Subjects taking antiarrhythmic, antiischemic, β-blocker, or calcium-channel blocker medications were also excluded from the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Xiao-dong Zhuang

department of cardiology, first affiliated hoapital of SYSU

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

zhimin du, MD

Role: PRINCIPAL_INVESTIGATOR

fitst affiliated hospital of SYSU

Locations

Xiaodong Zhaung

Guangzhou, Guangdong, China

Countries

China

Other Identifiers

PECS-sysu

Identifier Type: -

Identifier Source: org_study_id